Proteostasis Therapeutics, Inc. Announces Additions of Key Executives; Peter H. Reinhart Joins as CSO and Gregory P. Licholai is Appointed COO
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proteostasis Therapeutics announced today the appointments of Peter H. Reinhart, Ph.D., as Chief Scientific Officer and Gregory P. Licholai as Chief Operating Officer. Dr. Reinhart replaces interim CSO, Walter Newman, Ph.D., of Healthcare Ventures, who will remain with the company as a consultant.